Zmajkovicova, Katarina http://orcid.org/0000-0002-1394-7039
Pawar, Sumit
Maier-Munsa, Sabine
Maierhofer, Barbara
Wiest, Ivana
Skerlj, Renato
Taveras, Arthur G.
Badarau, Adriana
Funding for this research was provided by:
X4 Pharmaceuticals, Inc.
Article History
Received: 14 April 2022
Revised: 18 August 2022
Accepted: 22 August 2022
First Online: 12 September 2022
Competing interests
: X4 Pharmaceuticals funded the development of this paper. KZ, SP, SM, BM, IW, and AT are employees and KZ, SP, SM, BM, IW, and AT hold shares of X4 Pharmaceuticals, a clinical-stage company developing small molecule CXCR4 antagonists for the treatment of WHIM syndrome, WM, and other diseases. SP, RS, and AB were employees of X4 at the time of writing and are now former employees who hold shares in X4.